30 results
8-K
EX-99.1
EQ
Equillium Inc
25 Mar 24
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
4:05pm
: topline data expected in Q2 2024
Presented positive data from Phase 1b EQUALISE study of itolizumab in lupus nephritis patients at American Society
8-K
EX-99.2
l41za5k wu
8 Nov 23
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology
4:05pm
8-K
EX-99.1
mmyjw39 2ft
8 Nov 23
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology
4:05pm
424B5
33p1u cx5f6
5 Oct 23
Prospectus supplement for primary offering
5:23pm
8-K
EX-99.1
rp46 kvf9rdim
9 Aug 23
Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
4:06pm
8-K
EX-99.1
wzozke4ssud4wf
11 May 23
Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates
4:06pm
425
c2nb5v
27 Sep 22
Business combination disclosure
9:30am
8-K
EX-99.1
4upk ze7wqickqv
27 Sep 22
Other Events
9:28am
8-K
EX-99.1
p9x371stz iy
15 Aug 22
Equillium Reports Second Quarter 2022 Financial Results and Provides Clinical Development Updates
4:22pm
8-K
sf95rfk
25 Apr 22
Other Events
8:05am
8-K
EX-99.1
wpw4ssnh8jxbuzuedm
23 Mar 22
Equillium Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate & Clinical Development Updates
4:05pm